NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TRAW
Traws Pharma, Inc.
There isn't enough reported data to score TRAW yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
TRAW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TRAW's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
TRAW PE Valuation
TRAW has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
TRAW Forward outlook
There aren't enough analyst estimates for TRAW to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over TRAW on earnings quality, reporting a profit while its opponent remains loss making.
TRAW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.85 | +$26.27 |
| Q1 2026 | -$1.80 | +$147.96 |
| Q4 2025 | $0.82 | +$158.67 |
| Q3 2025 | -$19.65 | +$121.66 |
| Q2 2025 | -$28.12 | +$110.13 |
| Q1 2025 | -$149.76 | -$128.26 |
| Q4 2024 | -$157.85 | -$135.35 |
| Q3 2024 | -$141.31 | -$117.06 |
TRAW lost $1.85 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the stronger quarterly revenue trend. Revenue is up 2.1% for NVO versus down 100% for TRAW.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
TRAW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $2.7M | +4695% |
| Q1 2025 | $57K | +1.8% |
| Q4 2024 | $56K | 0% |
| Q3 2024 | $57K | 0% |
| Q2 2024 | $57K | 0% |
| Q1 2024 | $56K | 0% |
| Q4 2023 | $56K | 0% |
| Q3 2023 | $57K | 0% |
TRAW's revenue has picked up after four years of holding roughly level: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -46% | +216354 points |
| Q1 2025 | -9128% | +179 points |
| Q4 2024 | -9425% | -1457 points |
| Q3 2024 | -14975% | -6047 points |
| Q2 2024 | -216400% | -208312 points |
| Q1 2024 | -9307% | +1652 points |
| Q4 2023 | -7968% | +2271 points |
| Q3 2023 | -8928% | +968 points |
TRAW's operating margin was −46% last quarter, up 216354 points from the same quarter a year ago, near the top of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
TRAW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.6M | +$2.9M |
| Q4 2025 | -$2.8M | +$1.3M |
| Q1 2025 | -$5.4M | -$1M |
| Q4 2024 | -$4M | +$390K |
| Q1 2024 | -$4.4M | +$119K |
| Q4 2023 | -$4.4M | -$546K |
| Q2 2023 | -$4.5M | -$276K |
| Q1 2023 | -$4.5M | -$247K |
TRAW has burned cash in almost every quarter: −$18M over the past year, against −$24M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over TRAW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
TRAW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +49% | +5.2M shares |
| 1 year | +120% | +8.6M shares |
| 3 years | +1797% | +15M shares |
| 5 years | +3318% | +15.4M shares |
| Available history | +96762% | +15.8M shares |
TRAW has 16M diluted shares, up 120% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
TRAW Net Leverage
TRAW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
TRAW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 5.5 | Oversold |
TRAW's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TRAW PE vs Healthcare Sector
TRAW has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over TRAW on trend strength, trading above more of its moving averages.
TRAW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.39 | 28% below |
| 20 week MA | $0.50 | 44% below |
| 50 week MA | $1.19 | 76% below |
| 100 week MA | $2.12 | 87% below |
| 200 week MA | $9.74 | 97% below |
TRAW is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over TRAW on returns for 2026, with the stronger performance.
TRAW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $153.8 | $176.3 | +15% |
| 2021 | $176.3 | $71.3 | -60% |
| 2022 | $71.3 | $16.5 | -77% |
| 2023 | $16.5 | $18.8 | +14% |
| 2024 | $18.8 | $13.4 | -28% |
| 2025 | $13.4 | $1.17 | -91% |
| 2026 YTD | $1.17 | $0.28 | -76% |
TRAW has finished lower in four of the last six years. It's down 76% so far in 2026.